Warberg Asset Management’s NLS Pharmaceutics Warrant NLSPW Stock Holding History

Warberg Asset Management’s Portfolio NLSPW Stock Details NLSPW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,881	Closed	-$2K	–	303
2022 Q2	$2K	Sell	12,881 -10	-0.1%	-$2	﹤0.01%	245
2022 Q1	$5K	Buy	+12,891	New	+$4.57K	﹤0.01%	224
2021 Q4	–	Sell	-35,480	Closed	-$29K	–	214
2021 Q3	$29K	Sell	35,480 -4,631	-12%	-$4.29K	﹤0.01%	172
2021 Q2	$44K	Buy	40,111 +5,111	+15%	+$4.53K	0.01%	176
2021 Q1	$33K	Buy	+35,000	New	+$31.8K	0.01%	139

Other funds holding NLSPW

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Ayrton Capital Westport, Connecticut $14.7M AUM 12.82% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Warberg Asset Management's NLSPW Position: Q3 2022 in Review

Warberg Asset Management sold out of NLS Pharmaceutics Warrant (NLSPW) in Q3 2022, closing a stake of 12,881 shares — an estimated $2K sold.

Warberg Asset Management first reported a position in NLSPW in Q1 2021 and held it in 5 quarters. The position peaked at $44K in Q2 2021. 8 funds tracked by Wall St. Rank hold NLSPW as of Q3 2022.

Warberg Asset Management reported no remaining NLS Pharmaceutics Warrant position as of Q3 2022 after selling out during the quarter.
Warberg Asset Management sold 12,881 NLS Pharmaceutics Warrant shares in Q3 2022, an estimated $2K.
Warberg Asset Management first reported a position in NLS Pharmaceutics Warrant in Q1 2021 and held it in 5 quarters.
Warberg Asset Management's NLS Pharmaceutics Warrant position peaked at $44K in Q2 2021.
8 funds tracked by Wall St. Rank held NLS Pharmaceutics Warrant as of Q3 2022.

Based on Warberg Asset Management's 13F filing for Q3 2022, filed 7 Nov 2022.